Benzinga | Dec 21, 2021 05:13AM EST

Cantor Fitzgerald Downgrades Arena Pharmaceuticals to Neutral, Raises Price Target to $100

Cantor Fitzgerald analyst Alethia Young downgrades Arena Pharmaceuticals (NASDAQ:ARNA) from Overweight to Neutral and raises the price target from $93 to $100.